AEON Biopharma, Inc. announced plans to advance its biosimilar product ABP-450, leveraging the 351(k) regulatory pathway with the goal of obtaining FDA approval for all indications currently listed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results